Category: Due Diligence
-
Retailer Audit Readiness: What Major Nutraceutical Retailers Actually Require
When your nutraceutical company is ready to scale into major retail channels, the excitement of potential growth often meets the reality of nutraceutical retailer audit requirements. In our experience working with supplement manufacturers preparing for retail partnerships, understanding these requirements early transforms what could be a stressful scramble into a strategic advantage. Major retailers don’t… Read more
-
What Buyers Look For in a Regulatory Due Diligence Review
When private equity firms and strategic acquirers evaluate life sciences companies, the regulatory landscape often determines whether a promising deal moves forward or stalls indefinitely. Thorough regulatory due diligence can either validate an acquisition thesis or reveal hidden risks that fundamentally alter deal terms. For M&A buyers in the medtech, pharma, and nutraceutical sectors, understanding… Read more
-
The Difference Between a Compliance Audit and a Regulatory Readiness Check
The Difference Between a Compliance Audit and a Regulatory Readiness Check Understanding the distinction between a compliance audit and a regulatory readiness check is crucial for companies navigating the complex world of FDA regulations. While both assessments evaluate your organization’s adherence to regulatory requirements, they serve different purposes, occur at different stages of your business… Read more
-
What Health & MedTech Founders Should Fix Before Starting M&A Conversations
What Founders Should Fix Before Starting M&A Conversations The M&A landscape for life science has never been more competitive. While strategic acquirers and private equity firms actively seek innovative medtech, pharma, and nutraceutical companies, they’re increasingly selective about the deals they make. In our experience working with companies through acquisition processes, the consistently same critical… Read more
-
Red Flags That Kill Medtech and Pharma Deals at the Due Diligence Stage
Red Flags That Kill Medtech and Pharma Deals at the Due Diligence Stage Regulatory compliance issues have derailed countless medtech M&A transactions and pharma deals just as they approached the finish line. In our experience working with acquirers and investment firms over 25+ years, we consistently see the same critical due diligence red flags emerge… Read more
-
How Unresolved FDA Findings Affect Deal Valuation
How Unresolved FDA Findings Affect Deal Valuation When pharmaceutical and medical device companies enter acquisition discussions, buyers scrutinize every aspect of regulatory compliance. Among the most critical factors that can derail a deal or significantly impact valuation is an unresolved FDA warning letter. In our experience working with companies across the medtech and pharma sectors,… Read more
-
Why Regulatory Readiness is the Most Overlooked Factor in M&A Valuations
When private equity firms and strategic acquirers evaluate life sciences companies, they typically focus on market size, intellectual property, and potential for financial performance. Yet one critical factor consistently gets relegated to the back burner: regulatory readiness. Our 25+ years of experience with medtech, pharma, and nutraceutical companies has caused us to witness how regulatory… Read more
-
Why Regulatory Readiness is Essential for Founders Navigating M&A Conversations
As a founder, you’re no stranger to risk-taking… But when it comes to mergers, acquisitions, or divestitures, the stakes are higher than ever. These transactions aren’t just about aligning visions or expanding market share—they’re about managing risks that could impact your brand, your team, and your bottom line. And one of the most critical risks… Read more
-
How the CTI Regulatory Readiness Check for Due Diligence Differs from a Compliance Audit
Why Regulatory Readiness is Essential for Founders Navigating M&A Conversations As a founder, you’re no stranger to risk-taking. But when it comes to mergers, acquisitions, or divestitures, the stakes are higher than ever. These transactions aren’t just about aligning visions or expanding market share—they’re about managing risks that could impact your brand, your team, and… Read more